论文部分内容阅读
目的探讨固本防哮饮治疗支气管哮喘缓解期的可能作用机制。方法 36只小鼠随机分为正常组、模型组、孟鲁司特钠组及固本防哮饮低、中、高剂量组,每组6只。除正常组外其余各组通过采用卵蛋白致敏和呼吸道合胞病毒滴鼻建立支气管哮喘缓解期模型。末次激发后,固本防哮饮低、中、高剂量组分别给予固本防哮饮溶液12、24、36 g/(kg·d),孟鲁司特钠组给予孟鲁司特钠片2.6 mg/(kg·d),正常组、模型组给予蒸馏水20 ml/(kg·d),每日灌胃1次,共28天。检测各组小鼠肺组织中CCL24、CCR3、Muc5ac mRNA表达及p-STAT6、CCR3蛋白表达。结果与正常组比较,模型组小鼠肺组织中CCR3、Muc5ac mRNA及p-STAT6、CCR3蛋白表达水平均升高(P<0.05);与模型组比较,固本防哮饮高剂量组、孟鲁司特钠组均能降低CCL24、CCR3、Muc5ac mRNA及p-STAT6、CCR3蛋白表达水平(P<0.05)。结论固本防哮饮可能通过抑制STAT6蛋白活化,影响CCL24/CCR3结合及Muc5ac表达,从而抑制嗜酸性粒细胞募集和黏液高分泌,达到治疗支气管哮喘缓解期的目的。
Objective To investigate the possible mechanism of Guben anti-asthma drink in the treatment of bronchial asthma. Methods Thirty - six mice were randomly divided into normal group, model group, montelukast sodium group and Guben anti - asthma drink low, medium and high dose group, 6 mice in each group. In addition to the normal group the remaining groups through the use of ovalbumin sensitization and respiratory syncytial virus nasal drops bronchial asthma remission model was established. After the last challenge, Guben anti-asthma drink low, medium and high dose groups were given Guben anti-asthmatic solution 12,24,36 g / (kg · d), montelukast sodium group montelukast sodium tablets 2.6 mg / (kg · d). In the normal group, the model group was given distilled water 20 ml / (kg · d) once daily for 28 days. The expression of CCL24, CCR3 and Muc5ac mRNA and the expressions of p-STAT6 and CCR3 in the lung tissue of each group were detected. Results Compared with the normal group, the expression of CCR3 and Muc5ac mRNA and the expression of p-STAT6 and CCR3 in the lung tissue of the model group were significantly increased (P <0.05). Compared with the model group, Guben anti-asthmatic high-dose group, Lutous sodium group could reduce the expression of CCL24, CCR3, Muc5ac mRNA and p-STAT6, CCR3 protein (P <0.05). Conclusion Guben anti-asthma drink may inhibit the activation of STAT6 protein, affect the CCL24 / CCR3 binding and Muc5ac expression, thereby inhibiting eosinophil recruitment and mucus hypersecretion, to achieve the purpose of the treatment of bronchial asthma remission.